Attending acute and chronic wounds and burns

REVITY is a topical liquid or gel agent

REVITY® is a topical liquid or gel agent for use by healthcare practitioners in the cleansing of lesions of the skin and damaged dermal tissue during standard mechanical debridement procedures where such procedures are indicated. Topical application of REVITY as an adjunctive agent during debridement procedures disrupts the attachment of microbes, inflammatory factors and necrotic debris to underlying healthy tissues. This disruption by REVITY provides for enhanced removal of pathologic matter from the surface of lesions by established mechanical debridement techniques. REVITY does not contain antibiotics or antiseptic agents; however, application of REVITY can be used to reduce the number of microbes on a tissue surface by assisting in the physical removal of contaminated necrotized tissue debris.

A typical application of REVITY begins with layering, or irrigating, varying amounts, usually less than one milliliter, directly onto the surface of the damaged dermal tissue. This is performed after the chosen method of sharp debridement is performed. The product is left in place for 15 – 60 seconds then is removed with a water rinse.

REVITY can be characterized by its functionality as clinical tool that was designed to perform controlled, intense, instantaneous water extraction from the topmost layer of necrotized tissue on a lesion surface. REVITY essentially is a therapeutic instrument used to instantaneously convert necrotized tissues, microbial biofilm and other proinflammatory pathogenic substances on the surface of a dermal lesion into harmless devitalized tissue coagulum whenever and wherever that would be beneficial. It is expected that users of REVITY will adapt specific application techniques to best fit their own treatment protocols to provide the greatest clinical benefit possible to their patients.

In order to clearly demonstrate the entire mechanism of action of REVITY it is helpful to regard it as consisting of three separate concurrent processes and to discuss each process separately. The first is the process by which REVITY extracts water from tissue surfaces leading to tissue surface desiccation. The second is the process by which the tissue surface desiccation leads to formation of tissue surface coagulum. The third is the process by which the formation of the tissue surface coagulum provides clinical benefits.

REVITY is currently in the regulatory pathway for clearance in US and outside US.